Search CORE

123 research outputs found

Fig. 1 in An overview on the role of plant-derived tannins for the treatment of lung cancer

Author: Rajasekar Nandhine
Sivanantham Ayyanar
Ravikumar Vilwanathan
Rajasekaran Subbiah
Publication venue
Publication date: 31/08/2021
Field of study

Fig. 1. Molecular targets modulated by tannins in lung cancer. Tannins Abbreviations: CASU - casuarinin; EGCG - epigallocatechin-3-gallate; FPTF - fructus phyllanthi tannin fraction; GA – gallic acid; GERA - geraniin; GRA – granatin A; GRB – granatin B; GSPs - grape seed proanthocyanidins; GSPC - grape seed procyanidins; OEB - oenothein B; PAC – proanthocyanidin rich cranberry fraction; PARE – procyanidin rich extract from sorghum bran; PBOG - prodelphinidin B-2 3′-Ogallate; PCC – procyanidins from cinnamomi cortex; PCCC – procyanidin C1 from cinnamomi cortex; PRFR – proanthocyanidin rich fraction from red rice; TA - tannic acid; TT – total tannins. Abbreviations for molecules: AP-1 - Activator protein 1; Apaf-1 - Apoptotic protease activating factor 1; BAX - BCL2 Associated X; BCL2 - Bcell lymphoma 2; BCL-XL - B-cell lymphoma-extra large; CD31 - cluster of differentiation 31; CDK - cyclin dependent kinase; CDKN1A - cyclin-dependent kinase inhibitor; c-FLIP - FLICE-like inhibitory protein; Cip1/p21 - cyclin-dependent kinase inhibitor 1; COX-2 – cyclooxygenase-2; Cyt C - cytochrome C; E-Cad – E-cadherin; EMT – epithelial-to-mesenchymal transition; Fas - apoptosis antigen 1; FasL - Fas ligand; FN - fibronectin; GR – glutathione reductase; GSH – reduced glutathione; GST - glutathione S-transferase; 15-HETE - 15-hydroxyeicosatetraenoic acid; IGFBP-3 - insulin like factor binding protein 3; IGF-2R - insulin-like growth factor 2 receptor; Kip1/p27 - cyclin-dependent kinase inhibitor 1B; MAPK - mitogen-activated protein kinase; MDM2 - mouse double minute 2 homolog; mFasL - membrane-bound FasL; miR – microRNA; NANOG - transcriptional factor; N-cad - N-cadherin; NOX - NADPH oxidase; NF-kB - nuclear factor kappa-light-chainenhancer of activated B cells; NRF2 - nuclear factor erythroid 2 (NFE2)-related factor 2; NQO1 - NAD(P)H:quinone oxidoreductase; OCT-4 - octamer-binding transcription factor 4; PARP - poly-ADP ribose polymerase; PCNA - proliferating cell nuclear antigen; PGE2 - prostaglandin E2; 6-keto-PGF1α - 6-keto-prostaglandin F1α; PTEN - phosphatase and tensin homolog; PTGIS - prostacyclin synthase; pMDM2 – phospho mouse double minute 2 homolog; pAKT – phosphorylated protein kinase B; pERK1/2 – phosphorylated extracellular signal-regulated kinase 1/2; pJNK1/2 – phosphorylated c-Jun N-terminal kinase 1/2; pNF-kB - phosphorylated nuclear factor kappa-light-chain-enhancer of activated B cells; pPI3K – phosphorylated phosphatidylinositol 3-kinase; α-SMA – alpha-smooth muscle actin; pSmad2 – phosphorylated SMAD family member 2; pSmad3 – phosphorylated SMAD family member 3; p21/WAF1 - cyclin-dependent kinase inhibitor 1; p22phox - human neutrophil cytochrome b light chain; p47phox – neutrophil cytosol factor 1; pp38 – phosphorylated p38; Rb - retinoblastoma protein; sFasL - soluble FasL; Smac/ DIABLO - Second mitochondria-derived activator of caspase/direct inhibitor of apoptosis-binding protein with low pI; SNAIL1 - Zinc finger protein SNAI1; SOX2 - SRY (sex determining region Y)-box 2; pEGFR – phosphorylated epidermal growth factor receptor; TGF-βR1 - transforming growth factor beta receptor; UGT - uridine diphosphate glucuronosyl transferase; VIM - vimentin; VEGF - vascular endothelial growth factor; XIAP - X-linked inhibitor of apoptosis protein; ZO1 - Zonula occludens1. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)Published as part of Rajasekar, Nandhine, Sivanantham, Ayyanar, Ravikumar, Vilwanathan & Rajasekaran, Subbiah, 2021, An overview on the role of plant-derived tannins for the treatment of lung cancer, pp. 1-12 in Phytochemistry (112799) 188 on page 5, DOI: 10.1016/j.phytochem.2021.112799, http://zenodo.org/record/825915

Author Correction: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials

In the original version of this Perspective, the name of the author Giuseppe Curigliano was incorrectly written as Guiseppe Curigiliano. The affiliations have been corrected in the HTML and PDF versions of the manuscrip

Crossref

AIR Universita degli studi di Milano